Global health service company Cigna is on a mission: to get HopeLab’s cancer-fighting game app Re-Mission 2: Nanobot’s Revenge onto the phones and tablets of every young cancer patient in the world. The free app is available for Android and iOS (Apple) mobile devices.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/62267-cigna-hopelab-re-mission-2-mobile-app
Back App proven to improve back pain and prevent office workers from falling victim to Sitting Disease, is a chair that is very different from all others.
Back pain is a modern epidemic, with recent high profile victims including UK Prime Minister David Cameron, model Jodie Kidd and tennis ace Andy Murray.
With 80% of people experiencing some form of back pain in their lifetime and the rise of tablet computers creating a generation hunched over screens - dubbed the ‘iPosture’ generation – the Back App is more relevant than ever in the effort to combat Sitting Disease which, in addition to back pain, has been linked to cardiovascular illness and cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/51361-back-app-guarantee-improved-back-pain
Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65511-issels-integrative-immunotherapy-non-toxic-treatment-lung-cancer
Nearly six of ten Americans will develop kidney disease in their lifetime, according to a new analysis published in the American Journal of Kidney Diseases. In comparison, lifetime risk of diabetes, heart attack and invasive cancer is approximately four in ten.
As a result of this and previous studies, the National Kidney Foundation is calling on healthcare professionals to screen patients in specific high-risk groups for kidney disease – those age 60 or older and those with high blood pressure or diabetes – by adding a simple urine albumin test for kidney damage to annual physical examinations.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62772-national-kidney-foundation-study-screening-for-disease
More than 80,000 healthcare workers and their communities from across the country and around the world joined together in the Medline Pink Glove Dance for breast cancer online video competition. After a hard-fought dance battle, the online votes are in and Medline is pleased to name Geisinger Health System, Danville, Pa., as the winner. As a result, $25,000 will be donated to their charity of choice, the American Cancer Society, providing free transportation for treatment to central Pennsylvania breast cancer patients in need. Additionally, Medline and participating hospitals will donate another $1 million to the National Breast Cancer Foundation and various local breast cancer charities nationwide. More than $2.2 million has been donated through the campaign and Medline Foundation since 2005.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64450-medline-pink-glove-dance-video-competition-winners-breast-cancer-education
Phiten, the pioneer of AQUA-METAL™ materials and innovator of metal-infused technology, and professional baseball players C.J. Wilson, Josh Hamilton and J.B. Shuck have teamed up with Be The Match, the nonprofit organization dedicated to helping patients with blood cancers receive life-saving bone marrow and umbilical cord blood transplants. To support Be The Match and raise awareness of the national Be The Match Registry®, Phiten has designed a limited edition Phiten x Be The Match Tornado Necklace with sales benefiting the cause, and the three pro baseball players have been named Ambassadors of Hope by Be The Match.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64376-phiten-and-mlb-players-for-be-the-match-bone-marrow-donor-registry
Dune Medical Devices, Inc., announced today that its breakthrough intra-operative tissue assessment tool for early-stage breast cancer surgery, the MarginProbe System, has received Premarket Approval (PMA) by the United States Food and Drug Administration. The technology significantly improves surgeons’ ability to intra-operatively identify
Eagle Rare Kentucky Straight Bourbon Whiskey has named Angie Goodwin of Calhoun, Ky., as the winner of the Grand Prize 2014 Rare Life Award. Eagle Rare will donate $40,000 to Goodwin’s charity, Thumbs Up for Lane Goodwin Childhood Cancer Foundation, and host an awards ceremony in Henderson on March 7. Angie and her late son Lane started the foundation to support childhood cancer research through funding and advocacy and to assist families battling childhood cancer by providing education, financial assistance and a volunteer network.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64624-eagle-rare-bourbon-angie-goodwin-grand-prize-2014-rare-life-award
InSightec Ltd, the leader in magnetic resonance imaging (MRI)-guided Focused Ultrasound therapy, announced that the U.S. Food and Drug Administration (FDA) has approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56632-insightec-fda-approves-exablate
Pain can negatively affect a person’s quality of life and impede recovery from illness or injury. Recent research compiled by the American Massage Therapy Association (AMTA) suggests that massage can be a helpful pain management strategy for manually controlling symptoms in people suffering metastatic cancer and rheumatoid arthritis, among other illnesses, as well as post-cardiac surgery pain.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61665-amta-massage-therapy-for-pain-relief-cancer-arthritis-post-cardiac-surgery
Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient’s immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children’s Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64394-chop-penn-harness-engineered-t-cells-eliminate-tumors-in-blood-leukemia
